Clissold S P
Drugs. 1986;32 Suppl 4:46-59. doi: 10.2165/00003495-198600324-00005.
Since their synthesis in the late 1800s paracetamol (acetaminophen) and phenacetin have followed divergent pathways with regard to their popularity as mild analgesic/antipyretic drugs. Initially, paracetamol was discarded in favour of phenacetin because the latter drug was supposedly less toxic. Today the opposite is true, and paracetamol, along with aspirin, has become one of the two most popular 'over-the-counter' non-narcotic analgesic agents. This marked increase in the wide approval attained by paracetamol has been accompanied by the virtual commercial demise of phenacetin because of its role, albeit somewhat circumstantial, in causing analgesic nephropathy. Both paracetamol and phenacetin are effective mild analgesics, suitable for treating mild to moderate pain, and their actions are broadly comparable with those of aspirin and related salicylates, although they do not appear to possess significant anti-inflammatory activity. Since a major portion of a dose of phenacetin is rapidly metabolised to paracetamol, it seems possible that phenacetin owes some of its therapeutic activity to its main metabolite, paracetamol, whereas its most troublesome side effect (methaemoglobinaemia) is due to another metabolite, p-phenetidine. The mechanism of action of paracetamol is poorly defined, although it has been speculated that it may selectively inhibit prostaglandin production in the central nervous system, which would account for its analgesic/antipyretic properties. The lack of any significant influence on peripheral cyclooxygenase would explain the absence of anti-inflammatory activity. At therapeutic doses paracetamol is well tolerated and produces fewer side effects than aspirin. The most frequently reported adverse effect associated with paracetamol is hepatotoxicity, which occurs after acute overdosage (usually doses greater than 10 to 15g are needed) and, very rarely, during long term treatment with doses at the higher levels of the therapeutic range. Paracetamol damages the liver through the formation of a highly reactive metabolite which is normally inactivated by conjugation with glutathione. Overdoses of paracetamol exhaust glutathione stores, thus allowing the accumulation of this toxic metabolite which covalently binds with vital cell elements and can result in liver necrosis. Glutathione precursors (notably intravenous N-acetylcysteine) have proved remarkably successful in treating paracetamol overdose, as long as treatment is initiated within 10 hours.(ABSTRACT TRUNCATED AT 400 WORDS)
自19世纪末合成以来,对乙酰氨基酚(扑热息痛)和非那西丁作为轻度止痛/退烧药,其受欢迎程度经历了不同的发展路径。最初,对乙酰氨基酚被弃用而青睐非那西丁,因为后者据推测毒性较小。如今情况却相反,对乙酰氨基酚与阿司匹林一道,已成为两种最受欢迎的“非处方”非麻醉性止痛剂之一。对乙酰氨基酚获得广泛认可的显著增加,伴随着非那西丁在商业上几乎消失,因为它在导致止痛性肾病方面虽有些间接但有一定作用。对乙酰氨基酚和非那西丁都是有效的轻度止痛剂,适用于治疗轻至中度疼痛,它们的作用与阿司匹林及相关水杨酸盐大致相当,尽管它们似乎不具有显著的抗炎活性。由于一剂非那西丁的大部分会迅速代谢为对乙酰氨基酚,所以非那西丁的一些治疗活性可能归因于其主要代谢产物对乙酰氨基酚,而其最麻烦的副作用(高铁血红蛋白血症)则是由另一种代谢产物对氨基苯乙醚引起的。对乙酰氨基酚的作用机制尚不清楚,不过据推测它可能选择性抑制中枢神经系统中前列腺素的产生,这可以解释其止痛/退烧特性。对周围环氧化酶没有任何显著影响,则可以解释其缺乏抗炎活性。在治疗剂量下,对乙酰氨基酚耐受性良好,且产生的副作用比阿司匹林少。与对乙酰氨基酚相关的最常报告的不良反应是肝毒性,这在急性过量用药后发生(通常需要超过10至15克的剂量),并且在长期使用治疗范围较高水平剂量时非常罕见。对乙酰氨基酚通过形成一种高反应性代谢产物来损害肝脏,这种代谢产物通常通过与谷胱甘肽结合而失活。对乙酰氨基酚过量会耗尽谷胱甘肽储备,从而使这种有毒代谢产物积累,它会与重要的细胞成分共价结合并可能导致肝坏死。谷胱甘肽前体(特别是静脉注射N-乙酰半胱氨酸)已被证明在治疗对乙酰氨基酚过量方面非常成功,只要在10小时内开始治疗。(摘要截选至400字)